Cladribine, idarubicin, and cytarabine (CLIA) for patients with relapsed and/or refractory acute myeloid leukemia: A single‐center, single‐arm, phase 2 trial
CLIA is effective for patients with R/R AML and offers a safety profile similar to that of other intensive regimens (ClinicalTrials.gov identifier NCT02115295).
Authors
- Courtney Denton Dinardo (ORCID: https://orcid.org/0000-0001-9003-0390)
- Fadi Haddad (ORCID: https://orcid.org/0000-0002-9702-8485)
- Himachandana Atluri (ORCID: https://orcid.org/0000-0002-8867-7774)
- Tapan Mahendra Kadia (ORCID: https://orcid.org/0000-0002-9892-9832)
- Nitin Jain (ORCID: https://orcid.org/0000-0003-0114-8384)
- Kayleigh Marx (ORCID: https://orcid.org/0000-0001-9468-9707)
- Naval Guastad Daver (ORCID: https://orcid.org/0000-0001-7103-373X)
- Farhad Ravandi‐Kashani
- Elias Joseph Jabbour (ORCID: https://orcid.org/0000-0003-4465-6119)
- Musa E. Yilmaz (ORCID: https://orcid.org/0000-0002-4498-4895)
- Caitlin R. Rausch (ORCID: https://orcid.org/0000-0002-4166-5717)
- Gautam M. Borthakur (ORCID: https://orcid.org/0000-0001-7679-6453)
- Sanam Loghavi (ORCID: https://orcid.org/0000-0001-8980-3202)
- Guillermo Garcia‐Manero (ORCID: https://orcid.org/0000-0002-3631-2482)
- Yesid Alvarado (ORCID: https://orcid.org/0000-0002-1652-7937)
- Hannah Goulart (ORCID: https://orcid.org/0000-0002-1945-2571)
- Naveen Pemmaraju (ORCID: https://orcid.org/0000-0002-1670-6513)
- Hagop M. Kantarjian (ORCID: https://orcid.org/0000-0002-1908-3307)
Institutions
- The University of Texas MD Anderson Cancer Center (US)
Publication Details
- Journal
- Cancer
- Published
- 2025-04-07
- DOI
- https://doi.org/10.1002/cncr.35840
- Citations
- 1
- Primary Topic
- Acute Myeloid Leukemia Research
- Type
- article
- Field-Weighted Citation Impact
- 1.77
Funders
- National Institutes of Health